184 related articles for article (PubMed ID: 20886687)
1. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
[TBL] [Abstract][Full Text] [Related]
2. [Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin].
Siniashina LN; Nechaeva EV; Amelina IP; Karataev GI
Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):89-94. PubMed ID: 20095432
[TBL] [Abstract][Full Text] [Related]
3. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
Li R; Lim A; Alonso S
Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
[TBL] [Abstract][Full Text] [Related]
4. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
[TBL] [Abstract][Full Text] [Related]
5. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
6. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
7. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
Mielcarek N; Riveau G; Remoué F; Antoine R; Capron A; Locht C
Nat Biotechnol; 1998 May; 16(5):454-7. PubMed ID: 9592394
[TBL] [Abstract][Full Text] [Related]
8. Characterization of mutant strains producing pertussis toxin cross reacting materials.
Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of genetically inactivated pertussis toxin.
Brown DR; Keith JM; Sato H; Sato Y
Dev Biol Stand; 1991; 73():63-73. PubMed ID: 1778335
[TBL] [Abstract][Full Text] [Related]
10. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
[TBL] [Abstract][Full Text] [Related]
11. Bordetella pertussis from functional genomics to intranasal vaccination.
Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
[TBL] [Abstract][Full Text] [Related]
12. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
Cornford-Nairns R; Daggard G; Mukkur T
J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
[TBL] [Abstract][Full Text] [Related]
13. The advent of recombinant pertussis vaccines.
Burnette WN
Biotechnology (N Y); 1990 Nov; 8(11):1002-5. PubMed ID: 1366927
[No Abstract] [Full Text] [Related]
14. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
15. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.
Kavanagh H; Noone C; Cahill E; English K; Locht C; Mahon BP
Clin Exp Allergy; 2010 Jun; 40(6):933-41. PubMed ID: 20184606
[TBL] [Abstract][Full Text] [Related]
16. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
[TBL] [Abstract][Full Text] [Related]
17. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
[TBL] [Abstract][Full Text] [Related]
18. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
[TBL] [Abstract][Full Text] [Related]
19. Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice.
Mallaley PP; Halperin SA; Morris A; MacMillan A; Lee SF
Can J Microbiol; 2006 May; 52(5):436-44. PubMed ID: 16699568
[TBL] [Abstract][Full Text] [Related]
20. Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate.
Lim A; Ng JK; Locht C; Alonso S
Microbes Infect; 2014 Jan; 16(1):51-60. PubMed ID: 24140230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]